ACS study: Public perception of e-cigarettes vs. cigarettes harms changed sharply during EVALI epidemic and COVID-19 pandemic

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to.

February 06, 2026

Vol.52 No.05

By Robert A. Winn, Otis W. Brawley and Preston Willett

Podcast

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical News Analysis

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

The American Cancer Society’s 2026 annual statistics report trumpets a symbolic milestone for oncology—for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed between 2015 and 2021 in the U.S.

January 16, 2026

Vol.52 No.02

By Jacquelyn Cobb and Paul Goldberg

Podcast

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

“I believe in the concept of a universal cancer vaccine,” said Elias Sayour, a pediatric oncologist at the University of Florida. “I think if this fails in a prospective phase III trial, I still believe we can engineer a vaccine that works prospectively.”

January 14, 2026

Vol.52 No.1

Clinical

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.

January 09, 2026

Vol.52 No.1

By Sara Willa Ernst and Jacquelyn Cobb

Clinical Roundup

ACS cancer disparities report: Major differences in mortality burden by urbanicity, congressional district, socioeconomic status, and race/ethnicity

American Cancer Society scientists report higher cancer mortality rates among adults living in rural areas, certain congressional districts, and among those with lower socioeconomic status, according to a report published this month.

December 19, 2025

Vol.51 No.46

ACS study: Public perception of e-cigarettes vs. cigarettes harms changed sharply during EVALI epidemic and COVID-19 pandemic

YOU MAY BE INTERESTED IN

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

With five-year cancer survival at an all-time high, does this mean people are living longer?

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

ACS cancer disparities report: Major differences in mortality burden by urbanicity, congressional district, socioeconomic status, and race/ethnicity

Renew today!

Subscriber content

Never miss an issue!

Login

ACS study: Public perception of e-cigarettes vs. cigarettes harms changed sharply during EVALI epidemic and COVID-19 pandemic

YOU MAY BE INTERESTED IN

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

With five-year cancer survival at an all-time high, does this mean people are living longer?

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

ACS cancer disparities report: Major differences in mortality burden by urbanicity, congressional district, socioeconomic status, and race/ethnicity

Never miss an issue!

Login

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”